Abstract
Background The custom microenvironment 'vascular niche' is a potential therapeutic target for several pathophysiological conditions. Osteoblasts regulate the hematopoietic stem cell niche, and activation of the parathyroid hormone (PTH) receptor can increase the number of cells mobilized into the bloodstream.
Methods C57Bl/6 mice were randomly assigned treatment with granulocyte-colony stimulating factor (G-CSF), PTH, G-CSF plus PTH or saline. All mice underwent hindlimb ischemia. Blood flow was measured by laser Doppler imaging. Indices of capillary activity were determined by electron microscopy in muscle tissue. CD34+ and Ki67+ cells were detected and evaluated by immunofluorescence, apoptosis by TUNEL, surface antigen and endothelial progenitor cells by fluorescence-activated cell sorting analysis, and vascular endothelial growth factor-164 and angiopoietin-1 expression by reverse-transcriptase polymerase chain reaction. Frozen bone marrow sections were stained for antigen-specific B cells and fibronectin and analyzed by confocal laser scanning microscopy.
Results Following mobilization induced by G-CSF treatment, mice also treated with PTH showed increases in blood flow, capillary density, nitrite/nitrate release, angiogenic factors and circulating progenitor cells, as well as reduced apoptosis, fibrosis, oxidative stress and inflammation in ischemic muscles. Furthermore, hematopoietic antigen-specific B cells in the bone marrow were also increased by G-CSF alone and in combination with PTH.
Conclusions PTH might increase the efficiency of hematopoietic stem-cell-based therapy in a recognized model of peripheral ischemia. Our translational experimental therapeutic targeting of the vascular niche points to novel clinical targets for the hematopoietic stem-cell treatment of ischemic vascular diseases.
Key Points
-
The vascular niche is a potential therapeutic target for peripheral arterial disease
-
We present a translational research study investigating whether targeting the niche with parathyroid hormone (PTH) might improve stem cell-based therapy in an experimental model of hindlimb ischemia that would be relevant to the clinical use of hematopoietic stem-cell-driven angiogenesis
-
After mobilization induced by granulocyte-colony stimulating factor (G-CSF), mice also receiving PTH showed increased blood flow, capillary density, nitrite/nitrate release, angiogenic factors and circulating progenitor cells together with reduced apoptosis, fibrosis, oxidative stress and inflammation in ischemic muscles
-
Our translational study could stimulate clinical trials aimed at increasing the effectiveness of hematopoietic stem cell therapy in peripheral arterial disease by targeting the hematopoietic stem cell niche with PTH
-
In a recent phase I clinical trial,38 PTH (up to 100µg for 14 days) was tolerated well and there was no dose-limiting toxicity; thus, the clinical efficacy of PTH will need to be tested in a larger phase II study
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Krumholz HM and Masoudi FA (2006) The year in epidemiology, health services research, and outcomes research. J Am Coll Cardiol 48: 1886–1895
Napoli C et al. (2006) Rethinking primary prevention of atherosclerosis-related diseases. Circulation 114: 2517–2527
Napoli C et al. (2007) Bone marrow cell-mediated cardiovascular repair: potential of combined therapies. Trends Mol Med 13: 278–286
Taichman RS and Emerson SG (1994) Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 179: 1677–1682
Blair HC et al. (1999) Parathyroid hormone-regulated production of stem cell factor in human osteoblasts and osteoblast-like cells. Biochem Biophys Res Commun 255: 778–784
Taichman RS et al. (1996) Human osteoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures. Blood 87: 518–524
Calvi LM et al. (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841–846
Zhang J et al. (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425: 836–841
Kiel MJ et al. (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121: 1109–1121
Arai F et al. (2004) Tie2/Angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118: 149–161
Yin T and Li L (2006) The stem cell niches in bone. J Clin Invest 116: 1195–1201
Rixon RH et al. (1958) Increased survival of rats irradiated with x-rays and treated with parathyroid extract. Nature 182: 1374
Whitfield JF (2006) Parathyroid hormone: a novel tool for treating bone marrow depletion in cancer patients caused by chemotherapeutic drugs and ionizing radiation. Cancer Lett 244: 8–15
Schulze MR et al. (1993) Human parathyroid hormone dilates both pig coronary and human inferior epigastric arteries by a cyclic AMP-dependent pathway. Artery 20: 147–162
Rian E et al. (1994) Parathyroid hormone-related protein is produced by cultured endothelial cells: a possible role in angiogenesis. Biochem Biophys Res Commun 198: 740–747
Jiang B et al. (1998) Expression of parathyroid hormone/parathyroid hormone-related protein receptor in vascular endothelial cells. J Cardiovasc Pharmacol 31 (Suppl 1): S142–S144
Kalinowski L et al. (2001) Nitric oxide as a second messenger in parathyroid hormone-related protein signaling. J Endocrinol 170: 433–440
Napoli C et al. (2005) Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb. Proc Natl Acad Sci USA 102: 17202–17206
Minamino K et al. (2005) Macrophage colony-stimulating factor (M-CSF), as well as granulocyte colony-stimulating factor (G-CSF), accelerates neovascularization. Stem Cells 23: 347–354
Tan Y et al. (2007) Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor. Cardiovasc Res 73: 823–832
Egginton S et al. (1993) Fine structure of capillaries in ischaemic and non ischaemic rat striated muscle. Effect of torbafylline. Int J Microcirc Clin Exp 12: 33–44
Napoli C et al. (2003) Deletion of the p66Shc longevity gene reduces systemic and tisuue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed high-fat diet. Proc Natl Acad Sci USA 100: 2112–2116
Baker AH et al. (2007) Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proc Natl Acad Sci USA 104: 3597–3602
de Nigris F et al. (2007) Therapeutic effects of autologous bone marrow cells and metabolic intervention in the ischemic hindlimb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways. J Cardiovasc Pharmacol 50: 424–433
Casamassimi A et al. (2007) Comparison between total endothelial progenitor cell isolation versus enriched CD133+ culture. J Biochem 141: 503–511
de Nigris F et al. (2007) Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. Int J Cardiol 117: 238–243
Miranville A et al. (2004) Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 110: 349–355
Adams GB et al. (2007) Therapeutic targeting of a stem cell niche. Nat Biotechnol 25: 238–243
Zhou B et al. (2006) G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J Thromb Haemost 4: 993–1002
Kawamura A et al. (2006) Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 9: 226–233
Seggewiss R and Einsele H (2007) Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. Semin Hematol 44: 203–211
Nikolova G et al. (2007) The vascular niche and its basement membrane. Trends Cell Biol 17: 19–25
Lyman GH and Shayne M (2007) Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol 19: 299–307
Marsh JC et al. (2007) Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 44: 138–147
Feola M et al. (1985) Vasoactive parathyroid hormone in the treatment of acute ischemic left ventricular failure and the prevention of cardiogenic shock. Circ Shock 17: 163–177
Napoli C et al. (2007) Therapeutic approaches in vascular repair induced by adult bone marrow cells and circulating progenitor endothelial cells. Curr Pharm Des 13: 3245–3251
Herrmann J et al. (2006) Angiogenesis in atherogenesis. Arterioscler Thromb Vasc Biol 26: 1948–1957
Ballen KK et al. (2007) Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 13: 838–843
Zaruba et al. (2008) Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res 77: 722–731
Acknowledgements
These studies were supported by grants from the following institutions: Ministero dell'Università e Ricerca Scientifica PRIN 2006 to C Napoli and PRIN 2005 to A Giovane; Fondation Jerome Lejeune to C Napoli; NIH to S Williams-Ignarro, A Giordano, LJ Ignarro and C Napoli; Regione Campania 2007 to ML Balestrieri and C Napoli; Sbarro Research Institute to A Giordano; Ricerca di Ateneo 2006 and Camera di Commercio to the University of Sannio for FP Mancini and E Varricchio; and research funds of the University of Salerno to MF Tecce.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Napoli, C., William-Ignarro, S., Byrns, R. et al. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat Rev Cardiol 5, 571–579 (2008). https://doi.org/10.1038/ncpcardio1214
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1214
This article is cited by
-
Transplantation of mesenchymal stem cells improves type 1 diabetes mellitus
Cell and Tissue Research (2016)
-
Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation
Diabetologia (2013)
-
Arterial calcification and bone physiology: role of the bone–vascular axis
Nature Reviews Endocrinology (2012)
-
The mobilization of autologous bone marrow stem cells in the treatment of heart failure with Chinese medicine
Chinese Journal of Integrative Medicine (2011)
-
Stem cell niches as clinical targets: the future of anti-ischemic therapy?
Nature Clinical Practice Cardiovascular Medicine (2008)